RA Update: Draft Evidence Report
ICER’s Draft Evidence Report, open to public comment until November 8, 2019. For more information on submitting a public comment, please visit our stakeholder engagement page.
NOTE: After initially publishing an earlier version of this Draft Evidence Report on September 26, 2019, ICER’s internal reviewers identified the need to reevaluate some of the assumptions and calculations in the report to better align our economic modeling with how patients transition between these therapies in the real world. In our updated model, patients that are failed by first-line treatment now transition to a market basket of targeted immune modulators, instead of palliative care. Also, because clinical differentiation between these therapies is uncertain over time, we will now analyze their cost-effectiveness in the first year of use, instead of over a patient’s lifetime. See the introduction on Page 1 of this Draft Evidence Report for more details.View All Materials on this Topic or Go Back to View More Materials